Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
Abstract: Among the InSTI major RAM two (2.2%) sequences have Y143R and T97A mutations while one sample had T66I.
Result: Two (2%) patient had a viral sequences with Y143R major InSTI mutation in combination with the accessory T97A mutation, which confers high-level resistance to raltegravir (RAL), intermediate resistance to elvitegravir (EVG), and
Discussion: We confirmed Y143R in our study and this mutation in combination with T97A also impaired EVG susceptibility and showed possible low-level resistance.
Discussion: We observed the presence of Y143R in combination with T97A in one of our patients receiving ABC, 3TC, LPV/r.
Prevalence of HIV-1 Integrase Strand Transfer Inhibitor Resistance in Treatment-Naive Voluntary Counselling and Testing Clients by Population Sequencing and Illumina Next-Generation Sequencing in Taiwan.
Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naive and Experienced Individuals from Western India.
PMID: 30793915
2019
AIDS research and human retroviruses
Abstract: Other accessory mutations were L74IM (34.48%), Q95K (1.72%), and T97A (1.72%).
Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
PMID: 30380053
2019
The Journal of antimicrobial chemotherapy
Result: While no major mutation was described for dolutegravir resistance, we found some accessory integrase mutations in 98/524 (18.7%), such as L74I/M (n = 81/98, 82.7%), T97A (n = 8/98, 8.2%) and E157Q (n = 5/98, 5.1%), and more sporadically E138D/K (n = 2), V151I (n = 1) and G163R (n = 1).
Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
PMID: 30989237
2019
The Journal of antimicrobial chemotherapy
Result: No RAMs were observed to INSTIs; only the polymorphisms E157Q (n = 2), G163KR (n = 2) and T97A (n = 1) were observed, which have minimal effect on INSTI susceptibility.
Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
PMID: 31037930
2019
Revista espanola de quimioterapia
Table: T97A
Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naive individuals in a tertiary care hospital in Beijing, China.
Abstract: Two individuals harbored INSTI accessory mutations E157Q/T97A were detected for the first time.
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
Method: Primary INSTI resistance (-R) substitutions were T66I/A/K, E92Q/G, T97A, F121Y, Y143R/H/C, S147G, Q148H/K/R, N155H/S and R263K in IN
Result: Primary INSTI-R substitutions were infrequent (2.5%, 13/519) and consisted of T97A (1.7%, 9/519) and E92G, Q148H, S147G or Y143H (0.2%, 1/519 each).
Table: T97A
Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia.
Result: Furthermore, analysis of the integrase region revealed 3 accessory resistance mutations (T97A, Q146QH, D232N).
Discussion: We found only one major InSTI mutation (G140A), three accessory resistance mutations (T97A, Q146QH, D232N) and a very high prevalence of polymorphism S230N (49/100, 49%), which is not associated with reduced InSTI susceptibility.
Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence.
ViMRT
HIV mutation literature information.
PMID: 
2020
Frontiers in microbiology
